Androgens Modulate Bcl-2 Agonist of Cell Death (BAD) Expression and Function in Breast Cancer Cells
暂无分享,去创建一个
S. Catalano | S. Andò | M. Lanzino | C. Morelli | D. Sisci | I. Casaburi | R. Sirianni | M. Nocito | C. Chiodo | Alessandro Cormace
[1] E. Diamandis,et al. Transcriptome profiling and proteomic validation reveals targets of the androgen receptor signaling in the BT-474 breast cancer cell line , 2022, Clinical proteomics.
[2] Ying Sun,et al. Multicellular immune dynamics implicate PIM1 as a potential therapeutic target for uveitis , 2022, Nature Microbiology.
[3] U. Khoo,et al. Androgen Receptor as an Emerging Feasible Biomarker for Breast Cancer , 2022, Biomolecules.
[4] M. Lanzino,et al. The Other Side of the Coin: May Androgens Have a Role in Breast Cancer Risk? , 2021, International journal of molecular sciences.
[5] W. Tilley,et al. Arming androgen receptors to oppose oncogenic estrogen receptor activity in breast cancer , 2021, British Journal of Cancer.
[6] Jennifer L. Caswell-Jin,et al. Androgen receptor agonists as breast cancer therapeutics , 2021, Nature Medicine.
[7] I. Ellis,et al. The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer , 2021, Nature Medicine.
[8] J. J. Li,et al. Hormonal Carcinogenesis , 2020, Springer New York.
[9] Semin Lee,et al. Androgen-induced expression of DRP1 regulates mitochondrial metabolic reprogramming in prostate cancer. , 2019, Cancer letters.
[10] S. Baksh,et al. Non-canonical BAD activity regulates breast cancer cell and tumor growth via 14-3-3 binding and mitochondrial metabolism , 2019, Oncogene.
[11] S. Vowler,et al. The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome , 2018, Clinical Cancer Research.
[12] G. Gillet,et al. Subcellular Localization and Dynamics of the Bcl-2 Family of Proteins , 2018, Front. Cell Dev. Biol..
[13] E. Cheng,et al. The VDAC2–BAK axis regulates peroxisomal membrane permeability , 2017, The Journal of cell biology.
[14] W. Tilley,et al. Pushing estrogen receptor around in breast cancer. , 2016, Endocrine-related cancer.
[15] B. Boyan,et al. Rapid steroid hormone actions via membrane receptors. , 2016, Biochimica et biophysica acta.
[16] S. Verjovski-Almeida,et al. Identification of novel biomarkers associated with poor patient outcomes in invasive breast carcinoma , 2016, Tumor Biology.
[17] Xin Hu,et al. Androgen receptor expression predicts different clinical outcomes for breast cancer patients stratified by hormone receptor status , 2016, Oncotarget.
[18] S. Andò,et al. Androgens downregulate miR-21 expression in breast cancer cells underlining the protective role of androgen receptor , 2016, Oncotarget.
[19] Laura H. Tang,et al. Bcl-xL promotes metastasis independent of its anti-apoptotic activity , 2016, Nature Communications.
[20] S. Baek,et al. BCL-2 family protein, BAD is down-regulated in breast cancer and inhibits cell invasion. , 2015, Experimental cell research.
[21] C. Stournaras,et al. Inhibition of SGK1 enhances mAR-induced apoptosis in MCF-7 breast cancer cells , 2015, Cancer biology & therapy.
[22] P. Tan,et al. Androgen Receptor Expression Shows Distinctive Significance in ER Positive and Negative Breast Cancers , 2014, Annals of Surgical Oncology.
[23] I. Barone,et al. Estrogen receptor beta as a novel target of androgen receptor action in breast cancer cell lines , 2014, Breast Cancer Research.
[24] Muhammed A. Yıldırım,et al. Regulation of hepatic energy metabolism and gluconeogenesis by BAD. , 2014, Cell metabolism.
[25] R. Schwab,et al. Reproductive risk factors and breast cancer subtypes: a review of the literature , 2014, Breast Cancer Research and Treatment.
[26] Kaleigh Fernald,et al. Evading apoptosis in cancer. , 2013, Trends in cell biology.
[27] Takuji Iwase,et al. Clinical importance of androgen receptor in breast cancer patients treated with adjuvant tamoxifen monotherapy , 2013, Breast Cancer.
[28] Kyle C. Nelson,et al. BAD Dephosphorylation and Decreased Expression of MCL-1 Induce Rapid Apoptosis in Prostate Cancer Cells , 2013, PloS one.
[29] W. Gerald,et al. Expression of androgen receptor and its phosphorylated forms in breast cancer progression , 2013, Cancer.
[30] C. Giordano,et al. DAX-1, as an androgen-target gene, inhibits aromatase expression: a novel mechanism blocking estrogen-dependent breast cancer cell proliferation , 2013, Cell Death and Disease.
[31] G. Gillet,et al. Non-apoptotic roles of Bcl-2 family: the calcium connection. , 2013, Biochimica et biophysica acta.
[32] Wei-min Li,et al. Loss of Bad expression confers poor prognosis in non-small cell lung cancer , 2012, Medical Oncology.
[33] P. Argani,et al. Androgen receptor expression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsy. , 2012, Human pathology.
[34] J. Carroll,et al. Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene? , 2012, Molecular endocrinology.
[35] L. Pevny,et al. Human embryonic stem cells have constitutively active Bax at the Golgi and are primed to undergo rapid apoptosis. , 2012, Molecular cell.
[36] Sven Diederichs,et al. The hallmarks of cancer , 2012, RNA biology.
[37] R. Silverman,et al. Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers , 2011, Oncogene.
[38] L. Butler,et al. Differential effects of exogenous androgen and an androgen receptor antagonist in the peri- and postpubertal murine mammary gland. , 2011, Endocrinology.
[39] Carsten Denkert,et al. Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy , 2011, Breast Cancer Research and Treatment.
[40] Ricardo G. Correa,et al. Non-apoptotic role of BID in inflammation and innate immunity , 2011, Nature.
[41] Y. Niu,et al. Expression of androgen receptor in breast cancer and its significance as a prognostic factor. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[42] J. Martinou,et al. Mitochondrial outer membrane permeabilization during apoptosis: the role of mitochondrial fission. , 2011, Biochimica et biophysica acta.
[43] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[44] G. Colditz,et al. Androgen Receptor Expression and Breast Cancer Survival in Postmenopausal Women , 2011, Clinical Cancer Research.
[45] R. Tamimi,et al. Androgen Receptor Expression in Breast Cancer in Relation to Molecular Phenotype: Results from the Nurses’ Health Study , 2011, Modern Pathology.
[46] R. Jemmerson,et al. The proapoptotic function of Noxa in human leukemia cells is regulated by the kinase Cdk5 and by glucose. , 2010, Molecules and Cells.
[47] J. Mackey,et al. The BH3-only protein Bad confers breast cancer taxane sensitivity through a nonapoptotic mechanism , 2010, Oncogene.
[48] Z. Szallasi,et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients , 2010, Breast Cancer Research and Treatment.
[49] F. Sessa,et al. Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers , 2010, Virchows Archiv.
[50] F. Gao,et al. Expression of the apoptosis-related genes BCL-2 and BAD in human breast carcinoma and their associated relationship with chemosensitivity , 2010, Journal of experimental & clinical cancer research : CR.
[51] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.
[52] C. Giordano,et al. Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells—identification of a novel androgen response element , 2010, Nucleic acids research.
[53] M. Kampa,et al. Testosterone membrane‐initiated action in breast cancer cells: Interaction with the androgen signaling pathway and EPOR , 2010, Molecular oncology.
[54] B. Petit,et al. Prognostic significance of BAD and AIF apoptotic pathways in diffuse large B-cell lymphoma. , 2010, Clinical lymphoma, myeloma & leukemia.
[55] H. Park,et al. Expression of androgen receptors in primary breast cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[56] Rohit Bhargava,et al. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation , 2010, Modern Pathology.
[57] C. Stournaras,et al. Functional membrane androgen receptors in colon tumors trigger pro-apoptotic responses in vitro and reduce drastically tumor incidence in vivo , 2009, Molecular Cancer.
[58] Li Jia,et al. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. , 2009, Cancer research.
[59] S. Andò,et al. Insulin receptor substrate 1 modulates the transcriptional activity and the stability of androgen receptor in breast cancer cells , 2009, Breast Cancer Research and Treatment.
[60] W. Gerald,et al. Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer , 2009, Clinical Cancer Research.
[61] B. Brown,et al. Prognostic significance of Akt, phospho-Akt and BAD expression in primary breast cancer. , 2009, European journal of cancer.
[62] F. Grespi,et al. Bcl2 family proteins in carcinogenesis and the treatment of cancer , 2009, Apoptosis.
[63] G. Kallergi,et al. Membrane androgen receptor activation in prostate and breast tumor cells: Molecular signaling and clinical impact , 2009, IUBMB life.
[64] D. Sargent,et al. Proapoptotic Bad and Bid Protein Expression Predict Survival in Stages II and III Colon Cancers , 2008, Clinical Cancer Research.
[65] K. M. Leach,et al. Mitochondrial death pathways in yeast and mammalian cells. , 2008, Biochimica et biophysica acta.
[66] S. R. Datta,et al. Dual role of proapoptotic BAD in insulin secretion and beta cell survival , 2008, Nature Medicine.
[67] E. Levin,et al. Extranuclear steroid receptors: nature and actions. , 2007, Endocrine reviews.
[68] R. Sainson,et al. A Conserved Mechanism for Steroid Receptor Translocation to the Plasma Membrane* , 2007, Journal of Biological Chemistry.
[69] J. Bartlett,et al. Bad expression predicts outcome in patients treated with tamoxifen , 2007, Breast Cancer Research and Treatment.
[70] M. Almeida,et al. Classical genotropic versus kinase-initiated regulation of gene transcription by the estrogen receptor alpha. , 2006, Endocrinology.
[71] J. Yager,et al. Estrogen carcinogenesis in breast cancer. , 2006, The New England journal of medicine.
[72] Y. Lerenthal,et al. Proapoptotic BID Is an ATM Effector in the DNA-Damage Response , 2005, Cell.
[73] M. Kampa,et al. Opposing effects of estradiol- and testosterone-membrane binding sites on T47D breast cancer cell apoptosis. , 2005, Experimental cell research.
[74] J. Bentel,et al. Inhibition of MCF-7 breast cancer cell proliferation by 5alpha-dihydrotestosterone; a role for p21(Cip1/Waf1). , 2004, Journal of molecular endocrinology.
[75] S. R. Datta,et al. BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis , 2003, Nature.
[76] H. Denk,et al. Androgen receptors frequently are expressed in breast carcinomas , 2003, Cancer.
[77] S. R. Datta,et al. Bad-deficient mice develop diffuse large B cell lymphoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[78] S. R. Datta,et al. Survival factor-mediated BAD phosphorylation raises the mitochondrial threshold for apoptosis. , 2002, Developmental cell.
[79] S. Andò,et al. Breast cancer: from estrogen to androgen receptor , 2002, Molecular and Cellular Endocrinology.
[80] B. Katzenellenbogen,et al. Nongenotropic, Sex-Nonspecific Signaling through the Estrogen or Androgen Receptors Dissociation from Transcriptional Activity , 2001, Cell.
[81] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[82] Hans H. Zingg,et al. Inhibition of oxytocin receptor function by direct binding of progesterone , 1998, Nature.
[83] A. Strasser,et al. The anti‐apoptosis function of Bcl‐2 can be genetically separated from its inhibitory effect on cell cycle entry , 1997, The EMBO journal.
[84] Elizabeth Yang,et al. Serine Phosphorylation of Death Agonist BAD in Response to Survival Factor Results in Binding to 14-3-3 Not BCL-XL , 1996, Cell.
[85] C. Thompson,et al. Apoptosis in the pathogenesis and treatment of disease , 1995, Science.
[86] T. Thorsen,et al. Improved measurement of androgen receptors in human breast cancer. , 1989, Cancer research.
[87] G. Hortobagyi,et al. Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer. , 1979, Cancer research.
[88] A K Thilagar,et al. Steroid receptor analyses of nine human breast cancer cell lines. , 1978, Cancer research.
[89] L. Görlich,et al. Dihydrotestosterone receptor in human mammary cancer. , 1973, Acta endocrinologica. Supplementum.
[90] Y. Fouad,et al. Revisiting the hallmarks of cancer. , 2017, American journal of cancer research.
[91] J. Yun,et al. Decrease of Bcl-xL/Bcl-2-associated death promoter in hepatocellular carcinoma indicates poor prognosis. , 2015, American journal of cancer research.
[92] T. Myers,et al. Expression and location of pro-apoptotic Bcl-2 family protein BAD in normal human tissues and tumor cell lines. , 1998, The American journal of pathology.